drugset / Trial / NCT02340208
A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this research study is to evaluate how safe, how well tolerated and how effective a range of doses of L-DOS47 in patients with non-squamous non-small cell lung cancer when given as a monotherapy.
Timeline
- Start
- 2012-05
- Primary completion
- 2017-08-01
- Completion
- 2017-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | L-DOS47 | Other / unclassified | 0.12 ug/kg | — |
| Subject | L-DOS47 | Other / unclassified | 0.21 ug/kg | — |
| Subject | L-DOS47 | Other / unclassified | 0.33 ug/kg | — |
| Subject | L-DOS47 | Other / unclassified | 0.46 ug/kg | — |
| Subject | L-DOS47 | Other / unclassified | 0.59 ug/kg | — |
| Subject | L-DOS47 | Other / unclassified | 0.78 ug/kg | — |
| Subject | L-DOS47 | Other / unclassified | 1.04 ug/kg | — |
| Subject | L-DOS47 | Other / unclassified | 1.38 ug/kg | — |
| Subject | L-DOS47 | Other / unclassified | 1.84 ug/kg | — |
| Subject | L-DOS47 | Other / unclassified | 2.45 ug/kg | — |
| Subject | L-DOS47 | Other / unclassified | 3.26 ug/kg | — |
| Subject | L-DOS47 | Other / unclassified | 4.33 ug/kg | — |